Biologic Drug Shows Sustained Remission in Adult Ulcerative Colitis Patients Over Two Years

A recent two-year study indicates that a biologic drug achieved sustained remission in adult patients with inflammatory bowel disease (IBD). The data, which focuses on the treatment of ulcerative colitis, was recently presented. The study results, as reported in the *European Pharmaceutical Review*, highlight the potential of this biologic to maintain remission in adults suffering from IBD over an extended period. The findings contribute to the evolving understanding and management of ulcerative colitis.

Newsflash | Powered by GeneOnline AI
Date: May 5, 2025

Related posts:

Ignoring Intuition Increases Self-Blame, Study Finds Global Obesity Crisis: 1 in 6 Young People Predicted to Face Obesity by 2050, Study Warns Oral Wegovy Nears FDA Approval, Potentially Becoming First GLP-1 Weight-Loss Pill Company Cuts Three Advanced Drug Programs Due to Unsustainable Spending

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後